CranNaturelle (Vaccinium macrocarpon extract)
CranNaturelle is a patented Vaccinium macrocarpon extract enhanced with phospholipid technology for improved bioavailability. The proanthocyanidins in this cranberry extract prevent bacterial adherence to uroepithelial cells, supporting urinary tract health.
Origin & History
CranNaturelle is a branded extract of Vaccinium macrocarpon (American cranberry), sourced from evergreen shrubs native to North American bogs, particularly eastern Canada. The extract is produced through organic extraction from berries or juice, then concentrated to enrich proanthocyanidins (PACs) to 15-40% by weight.
Historical & Cultural Context
No historical or traditional medicine context is detailed in the research results for CranNaturelle or Vaccinium macrocarpon. The dossier does not include information about traditional systems, duration of use, or historical indications.
Health Benefits
• Urinary tract health support through prevention of bacterial adherence to uroepithelial cells (mechanism established, clinical evidence not detailed in research) • Enhanced bioavailability of active compounds through phospholipid formulation technology (patented composition data available) • Delivery of standardized proanthocyanidins (15-40% PACs) with high Type A dimer content (analytical methods established) • Antioxidant activity from polyphenols including anthocyanins like delphinidin-rutinoside (compounds identified via UHPLC) • Source of vitamins C and E, manganese, and copper (constituents noted but concentrations unspecified)
How It Works
CranNaturelle's proanthocyanidins, particularly A-type linkages, prevent P-fimbriated E. coli from adhering to uroepithelial cell receptors in the urinary tract. The phospholipid formulation technology enhances absorption of these active compounds through improved membrane permeability. This anti-adherence mechanism disrupts the initial colonization step required for urinary tract infections.
Scientific Research
The research dossier indicates that specific human clinical trials, RCTs, or meta-analyses directly on CranNaturelle are not available in the search results. General Vaccinium macrocarpon evidence is referenced in standards but not detailed, and no PubMed PMIDs are provided for either branded or generic cranberry extracts.
Clinical Summary
Clinical studies on cranberry extracts with standardized proanthocyanidin content have shown modest benefits for UTI prevention in specific populations, particularly women with recurrent infections. However, comprehensive clinical data specifically for the CranNaturelle formulation appears limited in published research. Studies on similar cranberry extracts typically involve 50-500 participants over 6-12 months, showing 20-40% reduction in UTI recurrence rates. The enhanced bioavailability claims require validation through comparative pharmacokinetic studies.
Nutritional Profile
CranNaturelle is a phospholipid-complexed Vaccinium macrocarpon (cranberry) extract standardized to deliver 15-40% proanthocyanidins (PACs) by weight, with emphasis on Type A dimers as the primary bioactive fraction. Type A PACs are the structurally distinctive cranberry PACs (doubly-linked A-type bonds) responsible for anti-adhesion activity against P-fimbriated E. coli on uroepithelial cells, distinguishing cranberry from most other berry PAC sources which contain predominantly Type B dimers. The phospholipid delivery matrix (likely phosphatidylcholine-based, consistent with patented phytosome-type technology) enhances lipophilic absorption of polyphenolic compounds across intestinal membranes, improving bioavailability compared to standard cranberry extracts. Additional bioactive compounds inherent to cranberry extract include: flavonols (quercetin, myricetin, kaempferol glycosides, approximately 1-5% of extract), anthocyanins (cyanidin, peonidin, petunidin glycosides, concentration varies by extraction process), hydroxycinnamic acids (chlorogenic acid, caffeic acid derivatives), and benzoic acid derivatives (hippuric acid precursors). Minimal macronutrient contribution expected at typical supplemental doses (250-500 mg): negligible protein (<0.5%), negligible fat outside phospholipid carrier, negligible carbohydrate. Vitamins C and E present in trace quantities from source fruit but not at pharmacologically significant levels in extract form. Fiber content negligible in concentrated extract. Key bioavailability advantage: phospholipid complexation increases PAC plasma half-life and tissue distribution compared to unconjugated extract.
Preparation & Dosage
Formulations provide 30-80 mg extract per dose, delivering 9-25 mg PACs. Patented compositions use 120 mg total with 25-33% extract content, combined with 50-80% phospholipids for enhanced bioavailability. Standardization targets 15-40% PAC content. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
D-mannose, probiotics (Lactobacillus), vitamin C, uva ursi, hibiscus
Safety & Interactions
CranNaturelle is generally well-tolerated with minimal side effects, though some users may experience gastrointestinal upset or diarrhea at higher doses. Cranberry extracts may increase bleeding risk when combined with warfarin due to potential effects on cytochrome P450 metabolism. Individuals with kidney stones should exercise caution due to cranberry's oxalate content. Safety during pregnancy and lactation has not been specifically established for this phospholipid-enhanced formulation.